<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362606</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-17018</org_study_id>
    <nct_id>NCT03362606</nct_id>
  </id_info>
  <brief_title>Engineered Immune Effectors Against Ovarian Cancer</brief_title>
  <official_title>Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of&#xD;
      ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer is a cancer that forms in or on an ovary. The majority of ovarian cancers&#xD;
      arise from the epithelium (outer lining) of the ovary. In 2015 it was reported found in 1.2&#xD;
      million women and resulted in 161,100 deaths worldwide. Among women it is the seventh-most&#xD;
      common cancer and the eighth-most common cause of death from cancer. Treatment for ovarian&#xD;
      cancer consists of surgery, chemotherapy, immunotherapy and sometimes, radiotherapy. The kind&#xD;
      of treatment depends on many factors, including the type of ovarian cancer, its stage and&#xD;
      grade, as well as the general health of the patient.&#xD;
&#xD;
      Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral&#xD;
      antigens has proven to be effective. Here, the investigators aim to evaluate the safety and&#xD;
      efficacy of multiple infusions of ovarian cancer specific cytotoxic T lymphocytes in&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of OC-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Physiological parameter (measuring cytokine response, fever, symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional analyses of OC-CTLs in vitro</measure>
    <time_frame>4 weeks</time_frame>
    <description>The specificity of OC-CTLs in vitro will be analysed by enzyme-linked immunospot assay (ELISPOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor effects</measure>
    <time_frame>1 year</time_frame>
    <description>Objective response, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>OC-CTLs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous ovarian cancer specific cytotoxic lymphocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OC-CTLs</intervention_name>
    <description>2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, abdominal cavity or tumor injection each time</description>
    <arm_group_label>OC-CTLs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written, informed consent obtained prior to any study-specific procedures.&#xD;
&#xD;
          2. Age older than 10 years.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.&#xD;
&#xD;
          4. Expected survival ≥ 12 weeks.&#xD;
&#xD;
          5. Histologically confirmed and documented high risk International Federation of&#xD;
             Gynecology and Obstetrics (FIGO): Stage II-IV.&#xD;
&#xD;
          6. Not pregnant, and on appropriate birth control if of childbearing potential.&#xD;
&#xD;
          7. Initial hematopoietic reconstitution with&#xD;
&#xD;
               -  neutrophils (ANC) ≥ 1,000/mm^3;&#xD;
&#xD;
               -  platelet (PLT) ≥ 100,000/mm^3.&#xD;
&#xD;
          8. Proper renal and hepatic functions (ULN denotes &quot;upper limit of normal range&quot;) with&#xD;
&#xD;
               -  serum creatinine ≤ 2×ULN;&#xD;
&#xD;
               -  serum bilirubin ≤ 2×ULN;&#xD;
&#xD;
               -  AST/ALT ≤ 2×ULN;&#xD;
&#xD;
               -  ALKP ≤ 5×ULN;&#xD;
&#xD;
               -  serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome.&#xD;
&#xD;
          9. Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test were negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with ovarian tumors with low malignant potential (i.e. borderline tumors);&#xD;
&#xD;
          2. Patients with evidence of abdominal free air not explained by paracentesis or recent&#xD;
             surgical procedure (prior, current or planned treatment).&#xD;
&#xD;
          3. Previous treatment of adoptive T cell therapy.&#xD;
&#xD;
          4. Current or recent treatment (within the 28-day period prior to Day 0) with another&#xD;
             investigational drug&#xD;
&#xD;
          5. Minor surgical procedures within 2 days prior to Day 0 (including central venous&#xD;
             access device placement for chemotherapy administration, tumor biopsies, needle&#xD;
             aspirations).&#xD;
&#xD;
          6. Pregnant or lactating females.&#xD;
&#xD;
          7. Inadequate bone marrow function with&#xD;
&#xD;
               -  absolute neutrophil count &lt; 1,000/mm^3;&#xD;
&#xD;
               -  platelet count &lt; 100,000/mm^3;&#xD;
&#xD;
               -  Hb &lt; 9 g/dL.&#xD;
&#xD;
          8. Inadequate liver and renal function with&#xD;
&#xD;
               -  serum (total) bilirubin &gt; 1.5 x ULN;&#xD;
&#xD;
               -  AST &amp; ALT &gt; 2.5 x ULN (&gt; 5 x ULN in patients with liver metastases);&#xD;
&#xD;
               -  alkaline phosphatase &gt; 2.5 x ULN;&#xD;
&#xD;
               -  serum creatinine &gt;2.0 mg/dl (&gt; 177 μmol/L);&#xD;
&#xD;
               -  urine dipstick for protein uria should be &lt; 2+. Patients with ≥ 2+ proteinuria on&#xD;
                  dipstick urinalysis at baseline should undergo 24 hour urine collection and must&#xD;
                  demonstrate &lt; 1 g of protein/24 hr.&#xD;
&#xD;
          9. Serious active infection requiring i.v. antibiotics at during screening.&#xD;
&#xD;
         10. Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), and HIV (HIV&#xD;
             antibody positive),Treponema pallidum antibody positive or TB culture positive.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Geno-Immune Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qichun Cai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jinshazhou Hospital of Guangzhou University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xun Lai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University &amp; Yunnan Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lung-Ji Chang, PhD</last_name>
    <phone>86-075586725195</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinshazhou Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510415</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qichun Cai, MD</last_name>
      <phone>86-13802830754</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Geno-immune Medical Institute</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Ji Chang, PhD</last_name>
      <phone>86-075586725195</phone>
      <email>c@szgimi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University &amp; Yunnan Cancer Center</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xun Lai, MD</last_name>
      <phone>13577096609</phone>
      <email>1729112214@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Geno-Immune Medical Institute</investigator_affiliation>
    <investigator_full_name>Lung-Ji Chang</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Cytotoxic lymphocyte</keyword>
  <keyword>OC-CTL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

